BDSX (Biodesix, Inc.) Stock Financials & Earnings

BDSXBiodesix, Inc.

Mkt Cap$151M

Revenue (TTM)$88M

Net Income (TTM)-$35M

EPS (TTM)-$4.85

Free Cash Flow (TTM)-$24M

Gross Margin81.1%

Op. Margin-31.5%

Net Margin-39.8%

FCF Margin-26.7%

P/S Ratio (TTM)1.7x

P/E Ratio (TTM)—

YoY Rev Growth+24.1%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$9M	$6M	-$16M
Q2 23	$12M	$9M	-$11M
Q3 23	$13M	$10M	-$7M
Q4 23	$15M	$11M	-$7M
Q1 24	$15M	$12M	-$11M
Q2 24	$18M	$14M	-$8M
Q3 24	$18M	$14M	-$9M
Q4 24	$20M	$16M	-$7M
Q1 25	$18M	$14M	-$9M
Q2 25	$20M	$16M	-$10M
Q3 25	$22M	$18M	-$7M
Q4 25	$29M	$24M	-$2M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$3M	—	$19M	—
Q2 23	$3M	—	—	$17M
Q3 23	$2M	—	—	$15M
Q4 23	$2M	$35M	—	—
Q1 24	$2M	—	—	$21M
Q2 24	$3M	—	—	$20M
Q3 24	$3M	—	—	$20M
Q4 24	$2M	—	—	$20M
Q1 25	$3M	—	—	$20M
Q2 25	$3M	—	—	$22M
Q3 25	$3M	—	—	$22M
Q4 25	$3M	—	—	$23M

Revenue Segments

Quarter	Diagnostic Tests	Service	Development Services
Q1 23	$9M	$411K	—
Q2 23	$11M	$423K	—
Q3 23	$12M	$1M	—
Q1 25	$16M	—	$2M
Q2 25	$18M	—	$2M
Q3 25	$20M	—	$2M
Q4 25	$25M	—	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$25M	$0	$25M
Q2 23	$17M	$0	$17M
Q3 23	$20M	$0	$20M
Q4 23	$26M	$0	$26M
Q1 24	$11M	$0	$11M
Q2 24	$42M	$0	$42M
Q3 24	$31M	$0	$31M
Q4 24	$26M	$0	$26M
Q1 25	$18M	$0	$18M
Q2 25	$21M	$0	$21M
Q3 25	$17M	$0	$17M
Q4 25	$19M	$0	$19M

Shares Outstanding

Revenue Per Employee

Revenue / Employee